ChromaDex Corporation - Common Stock (NQ:CDXC)

7.870 UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ChromaDex Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Earnings Scheduled For March 8, 2023 ↗

March 08, 2023

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.

Via Benzinga

Earnings Preview: ChromaDex ↗

March 07, 2023

Via Benzinga

This Analyst Cuts ChromaDex's Price Target On Revised Growth Trajectory ↗

August 29, 2022

Via Benzinga

ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023

March 06, 2023

From ChromaDex Corpor

Via Business Wire

ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023

February 27, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space

February 22, 2023

From ChromaDex Corporation

Via Business Wire

A Letter from the ChromaDex Chief Executive Officer

February 21, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

January 31, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

January 17, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

January 12, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Named Brianna Gerber Chief Financial Officer

January 05, 2023

From ChromaDex Corporation

Via Business Wire

ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States

November 11, 2022

From ChromaDex Corporation

Via Business Wire

ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

December 27, 2022

From ChromaDex Corporation

Via Business Wire

ChromaDex Corporation Reports Third Quarter 2022 Financial Results

November 02, 2022

From ChromaDex Corporation

Via Business Wire

Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday ↗

November 09, 2022

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.

Via Benzinga

Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session ↗

November 08, 2022

Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast...

Via Benzinga

ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022

October 26, 2022

From ChromaDex Corporation

Via Business Wire

ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards

October 24, 2022

From ChromaDex Corporation

Via Business Wire

ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment

October 11, 2022

From ChromaDex Corporation

Via Business Wire

$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying ↗

October 04, 2022

The Dow Jones jumped by more than 750 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 04, 2022

Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million.

Via Benzinga

ChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

October 04, 2022

From ChromaDex Corporation

Via Business Wire

Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)

September 19, 2022

From ChromaDex Corporation

Via Business Wire

ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock

October 03, 2022

From ChromaDex Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022 ↗

August 16, 2022

Via Benzinga

ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil

September 01, 2022

From ChromaDex Corporation

Via Business Wire

Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College

August 15, 2022

From ChromaDex Corporation

Via Business Wire

Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday ↗

August 12, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.

Via Benzinga

Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session ↗

August 11, 2022

Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2022 ↗

August 11, 2022

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.